#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Bob Steele @steele_bob @GERI1365 Great pic! #lcsm |
 | NCI Cancer Stats @NCICancerStats Death rates for #LungCancer have been falling on average 2.5% each year between 2005-2014. Learn more: https://t.co/JV6sVLEnLw #LCSM https://t.co/XpVifiPiDV |
 | Brendon Stiles @BrendonStilesMD You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: I've been sifting through 2000+ unique #WCLC2017 tweets--no way we'll cover everything in 60 min! But we'll have fun trying. #lcsm |
| Brendon Stiles @BrendonStilesMD To join, enter the URL “tchat.io” in your browser and type in #lcsm #lcsm |
 | Hossen Mahmud, MD @DrHMahmudMD RT @NCICancerStats: Death rates for #LungCancer have been falling on average 2.5% each year between 2005-2014. Learn more: https://t.co/JV6sVLEnLw #LCSM https://t.co/XpVifiPiDV |
 | Faces of Lung Cancer @LungCancerFaces Can't wait to see you again! DC here we come. RT @dennycee: Good evening. MI in the house. Just confirmed airbnb for 11/2 #433aday #lcsm |
| Brendon Stiles @BrendonStilesMD We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
 | Anita Figueras @scifiknitter Anita, currently in NYC. First scan results from erlotinib/trametinib combo clinical trial tomorrow. 😮 #lcsm |
 | Paula A @paulalv #lcsm Hi everyone |
 | Diane 🧚🏻♀️ @diianeee hello :) #lcsm |
| Brendon Stiles @BrendonStilesMD Good evening! Looking forward to a great chat and to hearing about all the #lcsm news from #wclc2017. #lcsm |
| Paula A @paulalv @dennycee #lcsm yay, we can't wait to see you |
 | Black Tina @bankszina #lcsm |
| Brendon Stiles @BrendonStilesMD I will announce FOUR topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
| Faces of Lung Cancer @LungCancerFaces Deana Hendrickson in Los Angeles here. Looking forward to tonight's chat. #lcsm |
| Brendon Stiles @BrendonStilesMD I’m your moderator Brendon Stiles, a thoracic surgeon, lung cancer researcher, and patient advocate. #lcsm |
 | Naomi @ChancesR3 NaomiF here in L A. Fresh fr USC Norris where husband evaluated today for durvalumab and AZD 6738 clinical trial. 5th line Hope! #lcsm |
 | Ian Pereira @IanJPereira RT @lcsmchat: TODAY! #LCSM Chat Th 10/19: World Conference on Lung Cancer #WCLC2017 Wrap-Up: TODAY! #LCSM Chat Th 10/19: World Conference on Lung Cancer #WCLC2017 Wrap-Up: https://t.co/oHJRmseSrK… Join us! @lysabee @IJohnPereira https://t.co/9yqc9uSkKW |
| Brendon Stiles @BrendonStilesMD We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm |
 | Janet Freeman-Daily @JFreemanDaily Janet Freeman-Daily in Seattle. It's fall. It's gray. It will be raining for the next six months. Time to visit with #LCSM tweeps! |
| Brendon Stiles @BrendonStilesMD T1. Why is the annual World Conference on Lung Cancer such an important meeting? #lcsm |
| Faces of Lung Cancer @LungCancerFaces @ChancesR3 So excited for you guys #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: Janet Freeman-Daily in Seattle. It's fall. It's gray. It will be raining for the next six months. Time to visit with #LCSM tweeps! |
 | #LCSM Chat @lcsmchat RT @GERI1365: Before we start have to share my 1st lil grandson’s 1st School Picture, your smile for today #LCSM https://t.co/eJTV8Wj9Ft |
 | Danielle Pardue @Actorielle RT @BrendonStilesMD: T1. Why is the annual World Conference on Lung Cancer such an important meeting? #lcsm |
| Brendon Stiles @BrendonStilesMD T1. #WCLC2017 has increasingly become gathering place that bridges all disciplines treating lung cancer – unique crosstalk. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: I've been sifting through 2000+ unique #WCLC2017 tweets--no way we'll cover everything in 60 min! But we'll have fun trying. #lcsm |
| Danielle Pardue @Actorielle Sorry I'm a little late, my friends...but I have pizza! #LCSM |
 | john @JohnLPender here 🙋♂️ #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: To join, enter the URL “tchat.io” in your browser and type in #lcsm #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Good evening! Looking forward to a great chat and to hearing about all the #lcsm news from #wclc2017. #lcsm |
| Brendon Stiles @BrendonStilesMD Good luck! RT @ChancesR3: NaomiF here in L A. Fresh fr USC Norris where husband evaluated today for durvalumab. Hope! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I will announce FOUR topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, lung cancer researcher, and patient advocate. #lcsm |
 | Deb Smith 🌻🟧 @debsmithbeach #LCSM Deb from NH here. |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| #LCSM Chat @lcsmchat RT @ChancesR3: NaomiF here in L A. Fresh fr USC Norris where husband evaluated today for durvalumab and AZD 6738 clinical trial. 5th line Hope! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Why is the annual World Conference on Lung Cancer such an important meeting? #lcsm |
| Brendon Stiles @BrendonStilesMD T1. #WCLC2017 runs the gamut of lung cancer – prevention, early diagnosis, surgery, radiation, oncology, palliative care #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1: #WCLC2017 was gathering of 7000 people from 85 countries, focused on #lungcancer detection, treatment & care #LCSM https://t.co/SUqdhxtj9n |
| Naomi @ChancesR3 @BrendonStilesMD Thanks @BrendonStilesMD !#lcsm |
| Brendon Stiles @BrendonStilesMD T1. - and weaves #science into all. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. #WCLC2017 runs the gamut of lung cancer – prevention, early diagnosis, surgery, radiation, oncology, palliative care #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1: @IASLC CEO Dr Fred Hirsch shared some highlights #WCLC2017 before the conference began #LCSM https://t.co/sWydIbHaBz https://t.co/gOjOmAoVKS |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: #WCLC2017 was gathering of 7000 people from 85 countries, focused on #lungcancer detection, treatment & care #LCSM https://t.co/SUqdhxtj9n |
| Naomi @ChancesR3 @LungCancerFaces Thanks so much D! Hope is addictive. #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: T1: T1: @IASLC CEO Dr Fred Hirsch shared some highlights #WCLC2017 before the conference began #LCSM https://t.co/sWydIbHaBz https://t.co/gOjOmAoVKS |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T1. #WCLC2017 runs the gamut of lung cancer – prevention, early diagnosis, surgery, radiation, oncology, palliative care #lcsm |
| Brendon Stiles @BrendonStilesMD T1. Includes incredibly broad group of stakeholders: MDs, scientists, nurses, industry, government officials – and patients/advocates! #lcsm |
| Faces of Lung Cancer @LungCancerFaces @IntrovertinNC Hence the "introvert" moniker. Welcome. #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T1: T1: @IASLC CEO Dr Fred Hirsch shared some highlights #WCLC2017 before the conference began #LCSM https://t.co/sWydIbHaBz https://t.co/gOjOmAoVKS |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T1. Includes incredibly broad group of stakeholders: T1. Includes incredibly broad group of stakeholders: MDs, scientists, nurses, industry, government officials – and patients/advocates! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Includes incredibly broad group of stakeholders: T1. Includes incredibly broad group of stakeholders: MDs, scientists, nurses, industry, government officials – and patients/advocates! #lcsm |
| Brendon Stiles @BrendonStilesMD @LungCancerFaces @IntrovertinNC Great use of "hence" on twitter. #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. Includes incredibly broad group of stakeholders: T1. Includes incredibly broad group of stakeholders: MDs, scientists, nurses, industry, government officials – and patients/advocates! #lcsm |
| Anita Figueras @scifiknitter @Actorielle It's a honeymoon tweet chat with @Actorielle ! 🎉 #lcsm |
| Black Tina @bankszina #lcsm currently waiting to get into clinical trial w/Nivolumab and cimavax |
| Brendon Stiles @BrendonStilesMD T1. I love that #WCLC2017 explores new cutting edge technology/science, but keeps everything in context of clinical utility. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @bankszina Best hopes! #lcsm |
 | Shankar Siva @_ShankarSiva T1 - I think #WCLC2017 is great to learn more about the other disciplines - it’s too easy to get caught in your own echo chamber #LCSM |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T1. #WCLC2017 runs the gamut of lung cancer – prevention, early diagnosis, surgery, radiation, oncology, palliative care #lcsm |
| Faces of Lung Cancer @LungCancerFaces @scifiknitter @Actorielle Now that's what I call dedication! #lcsm |
| Bob Steele @steele_bob RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other disciplines - it’s too easy to get caught in your own echo chamber #LCSM |
| Janet Freeman-Daily @JFreemanDaily T1: #WCLC2017 is a great opportunity for networking among #lungcancer researchers and clinicians #lcsm |
 | Tiffini Joseph @Smiles4Nana T1: what an amazing collaboration! #lcsm https://t.co/5215Tq8vmE |
| Brendon Stiles @BrendonStilesMD This is key to staying honest. RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other disciplines - #LCSM |
| Hossen Mahmud, MD @DrHMahmudMD RT @Smiles4Nana T1: what an amazing collaboration! #lcsm https://t.co/svoUhHlbLu |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. I love that #WCLC2017 explores new cutting edge technology/science, but keeps everything in context of clinical utility. #lcsm |
| #LCSM Chat @lcsmchat RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other disciplines - it’s too easy to get caught in your own echo chamber #LCSM |
| Brendon Stiles @BrendonStilesMD T1. @IASLC also taking lead in evaluating clinical/pathologic guidelines – a great job emphasizing access and quality care everywhere.#lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: #WCLC2017 is a great opportunity for networking among #lungcancer researchers and clinicians #lcsm |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: T1: T1: what an amazing collaboration! #lcsm https://t.co/5215Tq8vmE |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: This is key to staying honest. RT @_ShankarSiva: This is key to staying honest. RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other disciplines - #LCSM |
| colleen ziegler @ZieglerColleen #lcsm joining a little late Colleen in Rochester |
| Janet Freeman-Daily @JFreemanDaily T1: I think many #WCLC2017 participants are presently either on planes en route to home, or recovering from jet lag ... #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. @IASLC also taking lead in evaluating clinical/pathologic guidelines – a great job emphasizing access and quality care everywhere.#lcsm |
| Brendon Stiles @BrendonStilesMD Important question coming up next. #lcsm |
| Ian Pereira @IanJPereira @BrendonStilesMD Hi #lcsm! |
 | Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 @TomVargheseJr RT @Smiles4Nana: T1: T1: what an amazing collaboration! #lcsm https://t.co/5215Tq8vmE |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T1. @IASLC also taking lead in evaluating clinical/pathologic guidelines – a great job emphasizing access and quality care everywhere.#lcsm |
| Brendon Stiles @BrendonStilesMD T2. What is the role of patients and advocates at this meeting? #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T1: T1: #WCLC2017 is a great opportunity for networking among #lungcancer researchers and clinicians #lcsm |
| Danielle Pardue @Actorielle RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other disciplines - it’s too easy to get caught in your own echo chamber #LCSM |
| Janet Freeman-Daily @JFreemanDaily T2: @IASLC offered Patient Advocate Travel Awards to enable patients/advocates to attend #WCLC2017 #LCSM https://t.co/yNRqNPxpZc |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T1. I love that #WCLC2017 explores new cutting edge technology/science, but keeps everything in context of clinical utility. #lcsm |
| Brendon Stiles @BrendonStilesMD This. RT @MarksPhone: #lcsm What makes a conference valuable & important is engagement/commitment/focus..of knowledge, care, & hope |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. @IASLC also taking lead in evaluating clinical/pathologic guidelines – a great job emphasizing access and quality care everywhere.#lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: T2: T2: @IASLC offered Patient Advocate Travel Awards to enable patients/advocates to attend #WCLC2017 #LCSM https://t.co/yNRqNPxpZc |
| Janet Freeman-Daily @JFreemanDaily T2: #WCLC2017 "patient advocacy" track had presentations on patient/advocate research and initiatives to improve #lungcancer outcomes #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1: T1: I think many #WCLC2017 participants are presently either on planes en route to home, or recovering from jet lag ... #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. What is the role of patients and advocates at this meeting? #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T2: T2: @IASLC offered Patient Advocate Travel Awards to enable patients/advocates to attend #WCLC2017 #LCSM https://t.co/yNRqNPxpZc |
 | Gina @EAustin1969 Lurking #lcsm |
| Janet Freeman-Daily @JFreemanDaily T2: #lungcancer patients and advocates were among the featured voices on Twitter for #WCLC2017 #LCSM https://t.co/yPzrx8hOcu |
| Brendon Stiles @BrendonStilesMD Share this! RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to attend #WCLC2017 #LCSM https://t.co/zm45iueneF |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T2. What is the role of patients and advocates at this meeting? #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T2: T2: @IASLC offered Patient Advocate Travel Awards to enable patients/advocates to attend #WCLC2017 #LCSM https://t.co/yNRqNPxpZc |
| Danielle Pardue @Actorielle RT @cpeedell: |
| Brendon Stiles @BrendonStilesMD T2. @IASLC and #WCLC2017 are totally committed to patients/advocacy. Multiple advocacy sessions throughout meeting. #lcsm |
| Anita Figueras @scifiknitter RT @JFreemanDaily: T2: T2: #WCLC2017 "patient advocacy" track had presentations on patient/advocate research and initiatives to improve #lungcancer outcomes #LCSM |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T2: T2: #WCLC2017 "patient advocacy" track had presentations on patient/advocate research and initiatives to improve #lungcancer outcomes #LCSM |
| Brendon Stiles @BrendonStilesMD T2. Cover patient perspectives, psychosocial needs, patient reported outcomes, patient barriers, addressing stigma. Amazing breadth! #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T2. @IASLC and #WCLC2017 are totally committed to patients/advocacy. Multiple advocacy sessions throughout meeting. #lcsm |
| Faces of Lung Cancer @LungCancerFaces T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto next year. #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T2: T2: #lungcancer patients and advocates were among the featured voices on Twitter for #WCLC2017 #LCSM https://t.co/yPzrx8hOcu |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: Share this! RT @JFreemanDaily: T2: Share this! RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to attend #WCLC2017 #LCSM https://t.co/zm45iueneF |
 | Jill Feldman @jillfeldman4 @ivybelkins & I in Tokyo sending our hello! #WCLC2017 great learning & connecting. Exciting time for lc research #LCSM |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T2. @IASLC and #WCLC2017 are totally committed to patients/advocacy. Multiple advocacy sessions throughout meeting. #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: Share this! RT @JFreemanDaily: T2: Share this! RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to attend #WCLC2017 #LCSM https://t.co/zm45iueneF |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T2. Cover patient perspectives, psychosocial needs, patient reported outcomes, patient barriers, addressing stigma. Amazing breadth! #lcsm |
| Bob Steele @steele_bob RT @LungCancerFaces: T2: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto next year. #lcsm |
| Tiffini Joseph @Smiles4Nana @BrendonStilesMD T2: what better attendees than patients to advocate for themselves and their desired aspects of care #lcsm |
| Danielle Pardue @Actorielle RT @LungCancerFaces: T2: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto next year. #lcsm |
 | Sarah B @gilhuss RT @LungCancerFaces: T2: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto next year. #lcsm |
| BUY FOLLO₩ERS ,pod @juleedelosange1 RT @LungCancerFaces: T2: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto next year. #lcsm |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T1. Includes incredibly broad group of stakeholders: T1. Includes incredibly broad group of stakeholders: MDs, scientists, nurses, industry, government officials – and patients/advocates! #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Interesting to understand differences in patient perspective/advocacy Asia v. USA v. Europe v. Latin America v. everywhere else! #lcsm |
| #LCSM Chat @lcsmchat RT @cpeedell: |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T2: T2: #WCLC2017 "patient advocacy" track had presentations on patient/advocate research and initiatives to improve #lungcancer outcomes #LCSM |
| Danielle Pardue @Actorielle RT @Smiles4Nana: @BrendonStilesMD T2: @BrendonStilesMD T2: what better attendees than patients to advocate for themselves and their desired aspects of care #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T2: T2: #lungcancer patients and advocates were among the featured voices on Twitter for #WCLC2017 #LCSM https://t.co/yPzrx8hOcu |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T2. Interesting to understand differences in patient perspective/advocacy Asia v. USA v. Europe v. Latin America v. everywhere else! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. @IASLC and #WCLC2017 are totally committed to patients/advocacy. Multiple advocacy sessions throughout meeting. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Cover patient perspectives, psychosocial needs, patient reported outcomes, patient barriers, addressing stigma. Amazing breadth! #lcsm |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: T2: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto next year. #lcsm |
| Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 @TomVargheseJr RT @BrendonStilesMD: This is key to staying honest. RT @_ShankarSiva: This is key to staying honest. RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other disciplines - #LCSM |
| Brendon Stiles @BrendonStilesMD @Smiles4Nana This is true. Easy to get caught up in self importance at meetings. Have to remember all about patients. #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: @ivybelkins & I in Tokyo sending our hello! #WCLC2017 great learning & connecting. Exciting time for lc research #LCSM |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: @BrendonStilesMD T2: @BrendonStilesMD T2: what better attendees than patients to advocate for themselves and their desired aspects of care #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Interesting to understand differences in patient perspective/advocacy Asia v. USA v. Europe v. Latin America v. everywhere else! #lcsm |
| Ian Pereira @IanJPereira @BrendonStilesMD Great to hear that patients attended #WCLC2017! #lcsm |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T2. What is the role of patients and advocates at this meeting? #lcsm |
| Brendon Stiles @BrendonStilesMD @jillfeldman4 @ivybelkins What time is it there!? #lcsm |
| Faces of Lung Cancer @LungCancerFaces @jillfeldman4 @ivybelkins You ladies are having too much fun! I love all your photos/tweets! #lcsm |
| Janet Freeman-Daily @JFreemanDaily T2: Example: @GoldmanLisa, #ROS1 LC survivor, talks on ROS1ders in #WCLC2017 advocacy session #LCSM #LCAM https://t.co/Q8c3ERiU8G |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: Share this! RT @JFreemanDaily: T2: Share this! RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to attend #WCLC2017 #LCSM https://t.co/zm45iueneF |
| Janet Freeman-Daily @JFreemanDaily RT @IASLC: .@GoldmanLisa, #ROS1 LC survivor, talks on ROS1ders in #WCLC2017 advocacy session on raising awareness and building community. #LCSM #LCAM https://t.co/g6QVKqEJ2Y |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T2. @IASLC and #WCLC2017 are totally committed to patients/advocacy. Multiple advocacy sessions throughout meeting. #lcsm |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily @GoldmanLisa Great example of patients taking an active role. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: @Smiles4Nana This is true. Easy to get caught up in self importance at meetings. Have to remember all about patients. #lcsm |
| Shankar Siva @_ShankarSiva T1 - a lot of excitement about #ImmunoOnc at #WCLC2017 - do we worry about rising costs and choosing wisely in lung cancer? #LCSM |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T2: Example: T2: Example: @GoldmanLisa, #ROS1 LC survivor, talks on ROS1ders in #WCLC2017 advocacy session #LCSM #LCAM https://t.co/Q8c3ERiU8G |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @Smiles4Nana This is true. Easy to get caught up in self importance at meetings. Have to remember all about patients. #lcsm |
| #LCSM Chat @lcsmchat RT @IJohnPereira: @BrendonStilesMD Great to hear that patients attended #WCLC2017! #lcsm |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T2. Cover patient perspectives, psychosocial needs, patient reported outcomes, patient barriers, addressing stigma. Amazing breadth! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T2: Example: T2: Example: @GoldmanLisa, #ROS1 LC survivor, talks on ROS1ders in #WCLC2017 advocacy session #LCSM #LCAM https://t.co/Q8c3ERiU8G |
| Danielle Pardue @Actorielle RT @_ShankarSiva: T1 - a lot of excitement about #ImmunoOnc at #WCLC2017 - do we worry about rising costs and choosing wisely in lung cancer? #LCSM |
 | Geri Massa @GeriGerim13 I would love to be able to attend webinars live, or have library #LCSM |
| Janet Freeman-Daily @JFreemanDaily T2: Patients network with each other and experts in their type of cancer at #WCLC2017 #LCSM https://t.co/TEVipzZh7P |
| Brendon Stiles @BrendonStilesMD @_ShankarSiva Yes! We worry about this in T4 though! #lcsm |
| Hossen Mahmud, MD @DrHMahmudMD We have to remember about LC patients, particularly NSCLC and SCLC patients during the meeting which we participate. #LCSM |
| Bob Steele @steele_bob RT @_ShankarSiva: T1 - a lot of excitement about #ImmunoOnc at #WCLC2017 - do we worry about rising costs and choosing wisely in lung cancer? #LCSM |
| Ian Pereira @IanJPereira @BrendonStilesMD @JFreemanDaily @IASLC Interesting model to improve patient engagement at meetings! #lcsm #wclc2017 |
| Brendon Stiles @BrendonStilesMD T2 was great and got the crowd going. Here comes T3. #lcsm |
 | Lung Cancer Sux @LungCancerSux Thanks for all of the great representation! #LCSM |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T2. Interesting to understand differences in patient perspective/advocacy Asia v. USA v. Europe v. Latin America v. everywhere else! #lcsm |
| #LCSM Chat @lcsmchat RT @_ShankarSiva: T1 - a lot of excitement about #ImmunoOnc at #WCLC2017 - do we worry about rising costs and choosing wisely in lung cancer? #LCSM |
| Bob Steele @steele_bob RT @GERI1365: I would love to be able to attend webinars live, or have library #LCSM |
| #LCSM Chat @lcsmchat RT @GERI1365: I would love to be able to attend webinars live, or have library #LCSM |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T2: T2: Patients network with each other and experts in their type of cancer at #WCLC2017 #LCSM https://t.co/TEVipzZh7P |
| Brendon Stiles @BrendonStilesMD T3. What is new in cancer screening and early stage lung cancer? #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T2: T2: Patients network with each other and experts in their type of cancer at #WCLC2017 #LCSM https://t.co/TEVipzZh7P |
| Danielle Pardue @Actorielle RT @DrHMahmud: We have to remember about LC patients, particularly NSCLC and SCLC patients during the meeting which we participate. #LCSM |
| #LCSM Chat @lcsmchat RT @DrHMahmud: We have to remember about LC patients, particularly NSCLC and SCLC patients during the meeting which we participate. #LCSM |
| Ian Pereira @IanJPereira RT @Smiles4Nana: @BrendonStilesMD T2: @BrendonStilesMD T2: what better attendees than patients to advocate for themselves and their desired aspects of care #lcsm |
| #LCSM Chat @lcsmchat RT @IJohnPereira: @BrendonStilesMD @JFreemanDaily @IASLC Interesting model to improve patient engagement at meetings! #lcsm #wclc2017 |
| Brendon Stiles @BrendonStilesMD T3. I loved the idea of presenting a patient’s perspective on CT screening. Thanks @findlungcancer! #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. What is new in cancer screening and early stage lung cancer? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. What is new in cancer screening and early stage lung cancer? #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. I loved the idea of presenting a patient’s perspective on CT screening. Thanks @findlungcancer! #lcsm |
| Ian Pereira @IanJPereira @Smiles4Nana @BrendonStilesMD Curious to hear thoughts on how patient advocacy is received at these meetings. Moving forward? #lcsm #wclc2017 T2 |
| Tiffini Joseph @Smiles4Nana RT @BrendonStilesMD: T3. What is new in cancer screening and early stage lung cancer? #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Good lessons on engagement of high risk populations for screening (ID 10643). Overview -Liverpool Healthy Lung Project. #lcsm |
| Danielle Pardue @Actorielle RT @IJohnPereira: @Smiles4Nana @BrendonStilesMD Curious to hear thoughts on how patient advocacy is received at these meetings. Moving forward? #lcsm #wclc2017 T2 |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. Good lessons on engagement of high risk populations for screening (ID 10643). Overview -Liverpool Healthy Lung Project. #lcsm |
| Brendon Stiles @BrendonStilesMD One key to making screening work is getting the right populations to actually be screened! #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T3. Good lessons on engagement of high risk populations for screening (ID 10643). Overview -Liverpool Healthy Lung Project. #lcsm |
 | Dr. David Tom Cooke @DavidCookeMD T3 What was the engagement innovation in ID 10643? #LCSM https://t.co/kJKic8zBkn |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. I loved the idea of presenting a patient’s perspective on CT screening. Thanks @findlungcancer! #lcsm |
| #LCSM Chat @lcsmchat RT @IJohnPereira: @Smiles4Nana @BrendonStilesMD Curious to hear thoughts on how patient advocacy is received at these meetings. Moving forward? #lcsm #wclc2017 T2 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Good lessons on engagement of high risk populations for screening (ID 10643). Overview -Liverpool Healthy Lung Project. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: One key to making screening work is getting the right populations to actually be screened! #lcsm |
| Geri Massa @GeriGerim13 T3: would be great if it was part of normal testing ex. Mammograms, etc #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T3. I loved the idea of presenting a patient’s perspective on CT screening. Thanks @findlungcancer! #lcsm |
| Faces of Lung Cancer @LungCancerFaces THIS RT @BrendonStilesMD: One key to making screening work is getting the right populations to actually be screened! #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm |
| Tiffini Joseph @Smiles4Nana @BrendonStilesMD I feel the screening should include those with family hx, not just older, heavy smokers. #lcsm |
| Ian Pereira @IanJPereira RT @LungCancerFaces: T2: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto next year. #lcsm |
| Janet Freeman-Daily @JFreemanDaily T3: #WCLC2017 had some great presentations on how to decide whether a lung nodule required action #lcsm |
| Ian Pereira @IanJPereira @LungCancerFaces @IASLC Me, too :) #lcsm #wclc2017 #wclc2018 |
| Brendon Stiles @BrendonStilesMD T3. Also strong focus on quality assurance and training for CT screening. #lcsm |
| Faces of Lung Cancer @LungCancerFaces @GERI1365 Once we develop the right kind of test for the lower risk populations. #lcsm |
| Tiffini Joseph @Smiles4Nana RT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm |
| Dr. David Tom Cooke @DavidCookeMD T3 I think it is a provider (doctor) issue. #LCSM https://t.co/47V22OEmaE |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: One key to making screening work is getting the right populations to actually be screened! #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: One key to making screening work is getting the right populations to actually be screened! #lcsm |
| Danielle Pardue @Actorielle RT @GERI1365: T3: T3: would be great if it was part of normal testing ex. Mammograms, etc #lcsm |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: T3 What was the engagement innovation in ID 10643? #LCSM https://t.co/kJKic8zBkn |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm |
| Danielle Pardue @Actorielle RT @Smiles4Nana: @BrendonStilesMD I feel the screening should include those with family hx, not just older, heavy smokers. #lcsm |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T3. I loved the idea of presenting a patient’s perspective on CT screening. Thanks @findlungcancer! #lcsm |
| Danielle Pardue @Actorielle RT @DavidCookeMD: T3 I think it is a provider (doctor) issue. #LCSM https://t.co/47V22OEmaE |
| Brendon Stiles @BrendonStilesMD T3. Great updates on limited resection trials. Extremely low mortality (0% in Japanese trial). Will be new surgical standards. #lcsm |
| Tiffini Joseph @Smiles4Nana @DavidCookeMD T3: agreed. General practitioners especially don’t have a full understanding of who is at risk #lcsm |
 | Sarah Elizabeth @saraheliz1 RT @BrendonStilesMD: One key to making screening work is getting the right populations to actually be screened! #lcsm |
| Brendon Stiles @BrendonStilesMD @Smiles4Nana Clearly we have to identify risk factors other than just smoking. #lcsm |
| Sarah Elizabeth @saraheliz1 RT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm |
| Janet Freeman-Daily @JFreemanDaily .@findlungcancer had MANY great tweets about lung cancer screening presentations--search for her tweets #lcsm |
| Hossen Mahmud, MD @DrHMahmudMD It is helpful for saving lives, if we screen high-risk LC patients. #LCSM |
| Tiffini Joseph @Smiles4Nana @BrendonStilesMD Clearly 😉 #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. Great updates on limited resection trials. Extremely low mortality (0% in Japanese trial). Will be new surgical standards. #lcsm |
| Danielle Pardue @Actorielle RT @Smiles4Nana: @DavidCookeMD T3: @DavidCookeMD T3: agreed. General practitioners especially don’t have a full understanding of who is at risk #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Survival data from limited resection trials not mature, but will be important as we consider other local treatments – SBRT or RFA #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: @Smiles4Nana Clearly we have to identify risk factors other than just smoking. #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: .@findlungcancer had MANY great tweets about lung cancer screening presentations--search for her tweets #lcsm |
| Bob Steele @steele_bob Given relative low cost for LD CT, why are we not pressing more for scans for young & mid adult ages! #lcsm |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T3. Great updates on limited resection trials. Extremely low mortality (0% in Japanese trial). Will be new surgical standards. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD Some still think that the "jury is still out". The Jury is in, made their verdict, collected their per diem, and went back to work! #LCSM https://t.co/LKXeTCMugf |
| Brendon Stiles @BrendonStilesMD T3. Continue to see strong data from SBRT #radonc for treatment of early lung cancer. #lcsm |
| Faces of Lung Cancer @LungCancerFaces Nihilism among patients and PCPs is an issue MT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. #lcsm |
| Tiffini Joseph @Smiles4Nana #433aday should be a big indicator #lcsm https://t.co/H6tWE4NnP7 |
| Danielle Pardue @Actorielle RT @DrHMahmud: It is helpful for saving lives, if we screen high-risk LC patients. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm |
 | Enlightening Results 💡 @GraceCordovano Just saying hello and wishing you all a wonderful #LCSM chat tonight. In between meetings. Will catch up later. 🌸 |
| Diane 🧚🏻♀️ @diianeee THIS! RT @steele_bob: Given relative low cost for LD CT, why are we not pressing more for scans for young & mid adult ages! #lcsm |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: @BrendonStilesMD I feel the screening should include those with family hx, not just older, heavy smokers. #lcsm |
| Danielle Pardue @Actorielle RT @steele_bob: Given relative low cost for LD CT, why are we not pressing more for scans for young & mid adult ages! #lcsm |
| Brendon Stiles @BrendonStilesMD Did I just say this out loud? #lcsm |
 | IASLC @IASLC RT @LungCancerFaces: T2: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto next year. #lcsm |
| Danielle Pardue @Actorielle RT @DavidCookeMD: Some still think that the "jury is still out". The Jury is in, made their verdict, collected their per diem, and went back to work! #LCSM https://t.co/LKXeTCMugf |
| Janet Freeman-Daily @JFreemanDaily T3: I think I saw presentations about a screening study in China that included never smokers--increased diagnosis of #lungcancer #lcsm |
| Ian Pereira @IanJPereira #RadOnc https://t.co/tpAFb4JAlc |
| Danielle Pardue @Actorielle RT @LungCancerFaces: Nihilism among patients and PCPs is an issue MT @BrendonStilesMD: Nihilism among patients and PCPs is an issue MT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. Continue to see strong data from SBRT #radonc for treatment of early lung cancer. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: #WCLC2017 had some great presentations on how to decide whether a lung nodule required action #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Role of SBRT in operable patients remains undefined but solid arguments can be made on both sides. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD What was the abstract number? #LCSM https://t.co/AIpJKuoTH7 |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T3: T3: I think I saw presentations about a screening study in China that included never smokers--increased diagnosis of #lungcancer #lcsm |
| Shankar Siva @_ShankarSiva T3 - interestingly my resp. physician colleagues aren’t excited about screening in Oz - we are unlikely to do this anytime soon 🇦🇺 #LCSM |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T3. Continue to see strong data from SBRT #radonc for treatment of early lung cancer. #lcsm |
| Geri Massa @GeriGerim13 @LungCancerFaces #LCSM , what if over a certain age or if ANY Cancer in family, do a low dose Scan 1X a year. I don’t know what long term eff.on scans |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily This key. Be thoughtful and do no harm. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Also strong focus on quality assurance and training for CT screening. #lcsm |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: T3 I think it is a provider (doctor) issue. #LCSM https://t.co/47V22OEmaE |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Great updates on limited resection trials. Extremely low mortality (0% in Japanese trial). Will be new surgical standards. #lcsm |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: @DavidCookeMD T3: @DavidCookeMD T3: agreed. General practitioners especially don’t have a full understanding of who is at risk #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @Smiles4Nana Clearly we have to identify risk factors other than just smoking. #lcsm |
| Danielle Pardue @Actorielle RT @GERI1365: @LungCancerFaces #LCSM , what if over a certain age or if ANY Cancer in family, do a low dose Scan 1X a year. I don’t know what long term eff.on scans |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: .@findlungcancer had MANY great tweets about lung cancer screening presentations--search for her tweets #lcsm |
| #LCSM Chat @lcsmchat RT @DrHMahmud: It is helpful for saving lives, if we screen high-risk LC patients. #LCSM |
| Janet Freeman-Daily @JFreemanDaily @steele_bob Increasing age increases risk--younger people are not yet high enough risk to justify screening (so they say) #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Survival data from limited resection trials not mature, but will be important as we consider other local treatments – SBRT or RFA #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn't so Innocent #lcsm |
| Tiffini Joseph @Smiles4Nana #stigma! #lcsm https://t.co/upwQjAUIxP |
| Danielle Pardue @Actorielle RT @JFreemanDaily: @steele_bob Increasing age increases risk--younger people are not yet high enough risk to justify screening (so they say) #lcsm |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: Some still think that the "jury is still out". The Jury is in, made their verdict, collected their per diem, and went back to work! #LCSM https://t.co/LKXeTCMugf |
| Janet Freeman-Daily @JFreemanDaily @DavidCookeMD Would have to look for the tweet and do some sleuthing #lcsm |
 | Andrea Borondy Kitts @findlungcancer just popping in for a minute -- it's both; but obviously need docs to recommend similar to other types cancer screening #lcsm https://t.co/kQJn2e69sJ |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: Nihilism among patients and PCPs is an issue MT @BrendonStilesMD: Nihilism among patients and PCPs is an issue MT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. #lcsm |
| Brendon Stiles @BrendonStilesMD This is an important concept. Don't ignore or delay w/u of nodules in never smokers. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Continue to see strong data from SBRT #radonc for treatment of early lung cancer. #lcsm |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: #433aday should be a big indicator #lcsm https://t.co/H6tWE4NnP7 |
| Lung Cancer Sux @LungCancerSux RT @BrendonStilesMD: T3. Reminder that lung cancer in never smokers not an indolent disease: T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn't so Innocent #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: I think I saw presentations about a screening study in China that included never smokers--increased diagnosis of #lungcancer #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Role of SBRT in operable patients remains undefined but solid arguments can be made on both sides. #lcsm |
| Ian Pereira @IanJPereira @JFreemanDaily Interesting. Haven't seen much #lungcancer data from China. Unsurprising given the #airquality situation. Wonder what pathology tells #lcsm |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: What was the abstract number? #LCSM https://t.co/AIpJKuoTH7 |
| #LCSM Chat @lcsmchat RT @_ShankarSiva: T3 - interestingly my resp. physician colleagues aren’t excited about screening in Oz - we are unlikely to do this anytime soon 🇦🇺 #LCSM |
| Ian Pereira @IanJPereira RT @JFreemanDaily: T3: T3: I think I saw presentations about a screening study in China that included never smokers--increased diagnosis of #lungcancer #lcsm |
 | BUY FOLLO₩ERS ,abo @krapfnadia RT @JFreemanDaily: T3: T3: I think I saw presentations about a screening study in China that included never smokers--increased diagnosis of #lungcancer #lcsm |
| Brendon Stiles @BrendonStilesMD @cpeedell Hopefully a resounding "yes". #lcsm |
| Ian Pereira @IanJPereira #RadOnc https://t.co/prYryQZFoZ |
 | eqbal jamshed اقبال احمد جمشید @EJamshed RT @CUCancerCenter: Study finds breast cancer driver in 3 percent of lung cancers #LCSM #BCSM https://t.co/eBTK8y8Npf https://t.co/oLLiu2duns |
| Andrea Borondy Kitts @findlungcancer Agree - biomarkers - blood/plasma; breath; validated population risk prediction model inc 2nd hand smoke, pollution, genetics #lcsm https://t.co/tP9Q3vkJmT |
| Geri Massa @GeriGerim13 The Cancer center here offered a $99 low dose CT scan takes about 10 min. Had to qualify smoker, age, cancer family history #lcsm |
| Janet Freeman-Daily @JFreemanDaily T3: Soon to be published EU statement on #lungcancer screening in Europe #WCLC2017 #LCSM (H/T to @findlungcancer) https://t.co/D2BtaDTYBK |
| Ian Pereira @IanJPereira @_ShankarSiva What do you think may be driving less screening down under? #lcsm T3 |
| Brendon Stiles @BrendonStilesMD T3. And of course always love focus on quality of surgery and pathologic staging and evaluation. #lcsm |
| #LCSM Chat @lcsmchat RT @GERI1365: @LungCancerFaces #LCSM , what if over a certain age or if ANY Cancer in family, do a low dose Scan 1X a year. I don’t know what long term eff.on scans |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @JFreemanDaily This key. Be thoughtful and do no harm. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @steele_bob Increasing age increases risk--younger people are not yet high enough risk to justify screening (so they say) #lcsm |
| Lung Cancer Sux @LungCancerSux RT @JFreemanDaily: T3: T3: Soon to be published EU statement on #lungcancer screening in Europe #WCLC2017 #LCSM (H/T to @findlungcancer) https://t.co/D2BtaDTYBK |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Reminder that lung cancer in never smokers not an indolent disease: T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn't so Innocent #lcsm |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: #stigma! #lcsm https://t.co/upwQjAUIxP |
| #LCSM Chat @lcsmchat RT @findlungcancer: just popping in for a minute -- it's both; but obviously need docs to recommend similar to other types cancer screening #lcsm https://t.co/kQJn2e69sJ |
 | Siera Harris @sieraharris9271 RT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm |
| Brendon Stiles @BrendonStilesMD Going to shift to medical oncology and advanced disease soon. Lots of action. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: This is an important concept. Don't ignore or delay w/u of nodules in never smokers. #lcsm |
| #LCSM Chat @lcsmchat RT @cpeedell: |
| Dr. David Tom Cooke @DavidCookeMD Should be free by medicare and private insurance if fit the recommend risk factors. #LungCancerScreening #LCSM https://t.co/5rcrYHClF3 |
| #LCSM Chat @lcsmchat RT @IJohnPereira: @JFreemanDaily Interesting. Haven't seen much #lungcancer data from China. Unsurprising given the #airquality situation. Wonder what pathology tells #lcsm |
| Shankar Siva @_ShankarSiva T3 - super important studies. POSTLIV also running in China, SABRTOOTH in UK closed I hear? #LCSM @cpeedell https://t.co/qbKhnTqNNg |
| #LCSM Chat @lcsmchat RT @findlungcancer: Agree - biomarkers - blood/plasma; breath; validated population risk prediction model inc 2nd hand smoke, pollution, genetics #lcsm https://t.co/tP9Q3vkJmT |
| Janet Freeman-Daily @JFreemanDaily T3: #lungcancer screening in China @IASLC #WCLC2017 #lcsm https://t.co/EccZRS5i0y |
| Andrea Borondy Kitts @findlungcancer maybe depending on number relatives diagnosed & other risk factors e.g. 2nd hand smoke, pollution, radon #lcsm https://t.co/2dKSSA7cXv |
| Brendon Stiles @BrendonStilesMD @cpeedell "Beam vs. blade" sounds nice. I see video trailers... #lcsm |
| Geri Massa @GeriGerim13 You would 🤔 think the money potential savings by catching early would outweigh finding at Stg 3 & 4 #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: Soon to be published EU statement on #lungcancer screening in Europe #WCLC2017 #LCSM (H/T to @findlungcancer) https://t.co/D2BtaDTYBK |
| Brendon Stiles @BrendonStilesMD T4: What is new in advanced disease and medical oncology? #lcsm |
| eqbal jamshed اقبال احمد جمشید @EJamshed RT @findlungcancer: Positive Hospital Marketing Campaigns Have A Painful Downside : Shots - Health News : Positive Hospital Marketing Campaigns Have A Painful Downside : Shots - Health News : NPR #bcsm #lcsm https://t.co/wubwCVCMRY |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. And of course always love focus on quality of surgery and pathologic staging and evaluation. #lcsm |
| #LCSM Chat @lcsmchat RT @cpeedell: |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T3. Reminder that lung cancer in never smokers not an indolent disease: T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn't so Innocent #lcsm |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: Should be free by medicare and private insurance if fit the recommend risk factors. #LungCancerScreening #LCSM https://t.co/5rcrYHClF3 |
| Danielle Pardue @Actorielle RT @GERI1365: You would 🤔 think the money potential savings by catching early would outweigh finding at Stg 3 & 4 #lcsm |
| Danielle Pardue @Actorielle RT @findlungcancer: maybe depending on number relatives diagnosed & other risk factors e.g. 2nd hand smoke, pollution, radon #lcsm https://t.co/2dKSSA7cXv |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T3: T3: #lungcancer screening in China @IASLC #WCLC2017 #lcsm https://t.co/EccZRS5i0y |
| #LCSM Chat @lcsmchat RT @_ShankarSiva: T3 - super important studies. POSTLIV also running in China, SABRTOOTH in UK closed I hear? #LCSM @cpeedell https://t.co/qbKhnTqNNg |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3: T3: #lungcancer screening in China @IASLC #WCLC2017 #lcsm https://t.co/EccZRS5i0y |
| Brendon Stiles @BrendonStilesMD T4. Targeted therapy and immunotherapy bonanza! #lcsm |
| Danielle Pardue @Actorielle RT @DavidCookeMD: Should be free by medicare and private insurance if fit the recommend risk factors. #LungCancerScreening #LCSM https://t.co/5rcrYHClF3 |
| #LCSM Chat @lcsmchat RT @findlungcancer: maybe depending on number relatives diagnosed & other risk factors e.g. 2nd hand smoke, pollution, radon #lcsm https://t.co/2dKSSA7cXv |
| Tiffini Joseph @Smiles4Nana RT @GERI1365: You would 🤔 think the money potential savings by catching early would outweigh finding at Stg 3 & 4 #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T3: T3: Soon to be published EU statement on #lungcancer screening in Europe #WCLC2017 #LCSM (H/T to @findlungcancer) https://t.co/D2BtaDTYBK |
| Tiffini Joseph @Smiles4Nana @findlungcancer Exactly #lcsm |
| Faces of Lung Cancer @LungCancerFaces @BrendonStilesMD @cpeedell And a voice over done by a man with a deep, gravelly voice... #lcsm |
| Shankar Siva @_ShankarSiva @BrendonStilesMD T4 - FLAURA data for osimertinib pretty exciting for advanced eGFR NSCLC #LCSM |
| Janet Freeman-Daily @JFreemanDaily @findlungcancer! Welcome back! #lcsm |
| Danielle Pardue @Actorielle RT @Smiles4Nana: #stigma! #lcsm https://t.co/upwQjAUIxP |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4: T4: What is new in advanced disease and medical oncology? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Targeted therapy and immunotherapy bonanza! #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. Reminder that lung cancer in never smokers not an indolent disease: T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn't so Innocent #lcsm |
| #LCSM Chat @lcsmchat RT @_ShankarSiva: @BrendonStilesMD T4 - FLAURA data for osimertinib pretty exciting for advanced eGFR NSCLC #LCSM |
| Shankar Siva @_ShankarSiva RT @_ShankarSiva: T1 - a lot of excitement about #ImmunoOnc at #WCLC2017 - do we worry about rising costs and choosing wisely in lung cancer? #LCSM |
| Brendon Stiles @BrendonStilesMD T4. Emphasis on guidelines for molecular testing…from @RielyMD #lcsm https://t.co/RFSXDEjqwz |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T4: T4: What is new in advanced disease and medical oncology? #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T4. Targeted therapy and immunotherapy bonanza! #lcsm |
| Brendon Stiles @BrendonStilesMD @_ShankarSiva Yes..incredible. #LCSM |
| Danielle Pardue @Actorielle RT @_ShankarSiva: @BrendonStilesMD T4 - FLAURA data for osimertinib pretty exciting for advanced eGFR NSCLC #LCSM |
| Bob Steele @steele_bob Limiting scans to high risk factor profiles clearly isn't enough. We wait way too late! #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T4. Emphasis on guidelines for molecular testing…from @RielyMD #lcsm https://t.co/RFSXDEjqwz |
| Shankar Siva @_ShankarSiva T4 - ok on right topic now, thoughts for below? #lcsm https://t.co/c5LUZyPPJ3 |
| Danielle Pardue @Actorielle RT @steele_bob: Limiting scans to high risk factor profiles clearly isn't enough. We wait way too late! #lcsm |
| Brendon Stiles @BrendonStilesMD T4. Continue to see interesting data about EGFR TKI resistance and sequencing of therapy. From @DrRiyazShah #lcsm https://t.co/xc2iHM6HOe |
| Tiffini Joseph @Smiles4Nana @IntrovertinNC @LungCancerFaces @BrendonStilesMD @cpeedell Of course! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Emphasis on guidelines for molecular testing…from @RielyMD #lcsm https://t.co/RFSXDEjqwz |
| Janet Freeman-Daily @JFreemanDaily T4: Update on data for lorlatinib to treat ALK+ and ROS1+ NSCLC #WCLC2017 #LCSM https://t.co/JuilMOafVr |
| Tiffini Joseph @Smiles4Nana RT @steele_bob: Limiting scans to high risk factor profiles clearly isn't enough. We wait way too late! #lcsm |
| #LCSM Chat @lcsmchat RT @_ShankarSiva: T4 - ok on right topic now, thoughts for below? #lcsm https://t.co/c5LUZyPPJ3 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Continue to see interesting data about EGFR TKI resistance and sequencing of therapy. From @DrRiyazShah #lcsm https://t.co/xc2iHM6HOe |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T4. Continue to see interesting data about EGFR TKI resistance and sequencing of therapy. From @DrRiyazShah #lcsm https://t.co/xc2iHM6HOe |
| Brendon Stiles @BrendonStilesMD @_ShankarSiva Cost is definitely running crazy. I agree with idea of value based approval and PFS/OS endpoints. #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T4: T4: Update on data for lorlatinib to treat ALK+ and ROS1+ NSCLC #WCLC2017 #LCSM https://t.co/JuilMOafVr |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: Update on data for lorlatinib to treat ALK+ and ROS1+ NSCLC #WCLC2017 #LCSM https://t.co/JuilMOafVr |
| Brendon Stiles @BrendonStilesMD @cpeedell I want movie rights. #lcsm |
| Brendon Stiles @BrendonStilesMD T4. Liquid biopsies are hot! Need to balance convenience with decreased sensitivity and discordance w/ tissue. #lcsm |
| Andrea Borondy Kitts @findlungcancer Liverpool #lungcancer screening project patient engagement via GP was key factor @DavidCookeMD #lcsm https://t.co/qYgINR6gGK |
| Tiffini Joseph @Smiles4Nana T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM |
 | Matthew Katz, MD 🟦 @subatomicdoc RT @BrendonStilesMD: @JFreemanDaily This key. Be thoughtful and do no harm. #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T4. Continue to see interesting data about EGFR TKI resistance and sequencing of therapy. From @DrRiyazShah #lcsm https://t.co/xc2iHM6HOe |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @_ShankarSiva Cost is definitely running crazy. I agree with idea of value based approval and PFS/OS endpoints. #lcsm |
 | Acord@dinho @Acordadinho RT @findlungcancer: Positive Hospital Marketing Campaigns Have A Painful Downside : Shots - Health News : Positive Hospital Marketing Campaigns Have A Painful Downside : Shots - Health News : NPR #bcsm #lcsm https://t.co/wubwCVCMRY |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T4. Liquid biopsies are hot! Need to balance convenience with decreased sensitivity and discordance w/ tissue. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Liquid biopsies are hot! Need to balance convenience with decreased sensitivity and discordance w/ tissue. #lcsm |
| #LCSM Chat @lcsmchat RT @findlungcancer: Liverpool #lungcancer screening project patient engagement via GP was key factor @DavidCookeMD #lcsm https://t.co/qYgINR6gGK |
| Hossen Mahmud, MD @DrHMahmudMD For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agents. #LCSM |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: T4: T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM |
| Brendon Stiles @BrendonStilesMD @Smiles4Nana Great point. Have to make sure it is happening everywhere, because there are great treatments out there. #lcsm |
 | Denise Cutlip @dennycee Exactly https://t.co/tzv7G6OZG2 |
| Danielle Pardue @Actorielle RT @Smiles4Nana: T4: T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM |
| Shankar Siva @_ShankarSiva T3 & T4 aLots to be excited about with improvements from trials over the years in stage III (yellow) and stage IV NSCLV #LCSM @wallyjc https://t.co/uGDGsF7CyF |
| Danielle Pardue @Actorielle RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agents. #LCSM |
| Janet Freeman-Daily @JFreemanDaily @Smiles4Nana T4: Not enough patients getting reflex genomic testing, but liquid biopsies may soon help improve the situation. #lcsm |
| Anita Figueras @scifiknitter RT @BrendonStilesMD: T4. Liquid biopsies are hot! Need to balance convenience with decreased sensitivity and discordance w/ tissue. #lcsm |
| Lung Cancer Sux @LungCancerSux RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agents. #LCSM |
| Andrea Borondy Kitts @findlungcancer Ads Liverpool #lungcancer screening project @DavidCookeMD #lcsm https://t.co/8YVX7NbY3F |
| Tiffini Joseph @Smiles4Nana @BrendonStilesMD Those receiving tx by specialists. Unfortunately, so many are still being treated in the community #lcsm |
| Hossen Mahmud, MD @DrHMahmudMD For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agents. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: @Smiles4Nana Great point. Have to make sure it is happening everywhere, because there are great treatments out there. #lcsm |
| Danielle Pardue @Actorielle RT @_ShankarSiva: T3 & T4 aLots to be excited about with improvements from trials over the years in stage III (yellow) and stage IV NSCLV #LCSM @wallyjc https://t.co/uGDGsF7CyF |
| #LCSM Chat @lcsmchat RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agents. #LCSM |
| Brendon Stiles @BrendonStilesMD T4. Interesting data about mutation burden and small cell. From @peters_solange. When will see routine use of IO for small cell? #lcsm https://t.co/AaKGTjGkHt |
| Lung Cancer Sux @LungCancerSux RT @JFreemanDaily: @Smiles4Nana T4: @Smiles4Nana T4: Not enough patients getting reflex genomic testing, but liquid biopsies may soon help improve the situation. #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: @Smiles4Nana T4: @Smiles4Nana T4: Not enough patients getting reflex genomic testing, but liquid biopsies may soon help improve the situation. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @Smiles4Nana Great point. Have to make sure it is happening everywhere, because there are great treatments out there. #lcsm |
| #LCSM Chat @lcsmchat RT @_ShankarSiva: T3 & T4 aLots to be excited about with improvements from trials over the years in stage III (yellow) and stage IV NSCLV #LCSM @wallyjc https://t.co/uGDGsF7CyF |
| Bob Steele @steele_bob RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agents. #lcsm |
| Tiffini Joseph @Smiles4Nana RT @JFreemanDaily: @Smiles4Nana T4: @Smiles4Nana T4: Not enough patients getting reflex genomic testing, but liquid biopsies may soon help improve the situation. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @Smiles4Nana T4: @Smiles4Nana T4: Not enough patients getting reflex genomic testing, but liquid biopsies may soon help improve the situation. #lcsm |
| #LCSM Chat @lcsmchat RT @findlungcancer: Ads Liverpool #lungcancer screening project @DavidCookeMD #lcsm https://t.co/8YVX7NbY3F |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: @BrendonStilesMD Those receiving tx by specialists. Unfortunately, so many are still being treated in the community #lcsm |
| Naomi @ChancesR3 @DrHMahmud @LungCancerSux Yes - this is such a game-changer. #lcsm |
| #LCSM Chat @lcsmchat RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agents. #lcsm |
| Andrea Borondy Kitts @findlungcancer Many smokers in Liverpool: smoking everywhere @DavidCookeMD #lcsm https://t.co/Ug1uxm6aDW |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Interesting data about mutation burden and small cell. From @peters_solange. When will see routine use of IO for small cell? #lcsm https://t.co/AaKGTjGkHt |
| Danielle Pardue @Actorielle RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agents. #lcsm |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily @Smiles4Nana I think this is going to definitely be true. #lcsm |
| Janet Freeman-Daily @JFreemanDaily T4: Entrectinib is very promising drug for #ROS1 patients, and treats brain mets. #WCLC2017 #LCSM https://t.co/28rQz19A4X |
| Janet Freeman-Daily @JFreemanDaily T4: nivolumab efficacy enhanced in SCLC with high Tumor Mutation Burden (TMB) w/ or w/o ipilimumab #WCLC2017 #LCSM https://t.co/efZGG8ybsc |
| Bob Steele @steele_bob RT @JFreemanDaily: T4: T4: Entrectinib is very promising drug for #ROS1 patients, and treats brain mets. #WCLC2017 #LCSM https://t.co/28rQz19A4X |
| Andrea Borondy Kitts @findlungcancer The results by the numbers Liverpool #lungcancer screening project #lcsm https://t.co/wysFTMlH1U |
| Brendon Stiles @BrendonStilesMD T4. Agree_Interesting things happening for ROS1: standardtesting, entrectinib treatment. From @MSPneu #lcsm https://t.co/q8BGjwMp9w |
| Tiffini Joseph @Smiles4Nana @BrendonStilesMD @JFreemanDaily This is why education and advocacy is such an integral piece of progress #lcsm |
| Danielle Pardue @Actorielle RT @cpeedell: |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T4: T4: Entrectinib is very promising drug for #ROS1 patients, and treats brain mets. #WCLC2017 #LCSM https://t.co/28rQz19A4X |
| Dr. David Tom Cooke @DavidCookeMD One of the roles of #LCSM movement. "Education and Advocacy". https://t.co/tPkqhRkknE |
| Brendon Stiles @BrendonStilesMD @cpeedell @_ShankarSiva Across the board. Not sustainable at current rate. But access is key. #lcsm |
| #LCSM Chat @lcsmchat RT @cpeedell: |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: Entrectinib is very promising drug for #ROS1 patients, and treats brain mets. #WCLC2017 #LCSM https://t.co/28rQz19A4X |
| Enlightening Results 💡 @GraceCordovano @JFreemanDaily @Smiles4Nana No. Not universally recommended. Not fully reimbursed. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4: T4: nivolumab efficacy enhanced in SCLC with high Tumor Mutation Burden (TMB) w/ or w/o ipilimumab #WCLC2017 #LCSM https://t.co/efZGG8ybsc |
| Danielle Pardue @Actorielle RT @findlungcancer: The results by the numbers Liverpool #lungcancer screening project #lcsm https://t.co/wysFTMlH1U |
| #LCSM Chat @lcsmchat RT @findlungcancer: The results by the numbers Liverpool #lungcancer screening project #lcsm https://t.co/wysFTMlH1U |
| #LCSM Chat @lcsmchat RT @cpeedell: |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Agree_Interesting things happening for ROS1: T4. Agree_Interesting things happening for ROS1: standardtesting, entrectinib treatment. From @MSPneu #lcsm https://t.co/q8BGjwMp9w |
| Tiffini Joseph @Smiles4Nana @DavidCookeMD So true! #lcsm proud to be a part of it! |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: @BrendonStilesMD @JFreemanDaily This is why education and advocacy is such an integral piece of progress #lcsm |
| Danielle Pardue @Actorielle RT @DavidCookeMD: One of the roles of #LCSM movement. "Education and Advocacy". https://t.co/tPkqhRkknE |
| #LCSM Chat @lcsmchat RT @DavidCookeMD: One of the roles of #LCSM movement. "Education and Advocacy". https://t.co/tPkqhRkknE |
| Dr. David Tom Cooke @DavidCookeMD RT @Smiles4Nana: @DavidCookeMD So true! #lcsm proud to be a part of it! |
| Brendon Stiles @BrendonStilesMD T4. Still bouncing around - who should get frontline immunotherapy for NSCLC? #lcsm |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: @DavidCookeMD So true! #lcsm proud to be a part of it! |
| Bob Steele @steele_bob RT @BrendonStilesMD: T4. Still bouncing around - who should get frontline immunotherapy for NSCLC? #lcsm |
 | Treatment for Cancer @cancer_tm RT @JFreemanDaily: T1: T1: #WCLC2017 is a great opportunity for networking among #lungcancer researchers and clinicians #lcsm |
| Naomi @ChancesR3 @EdenLake @steele_bob Even late stage. My husband being eval for 5th line treatment - duvalumab and AZD6738. Immunotherapy that might work with EGFR. #lcsm #hope |
| Tiffini Joseph @Smiles4Nana @GraceCordovano @JFreemanDaily I feel like saving lives should always be universally recommended #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Still bouncing around - who should get frontline immunotherapy for NSCLC? #lcsm |
 | Sakshi Saini @Sakshi1185 RT @Tony_Calles: |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T4. Still bouncing around - who should get frontline immunotherapy for NSCLC? #lcsm |
| Bob Steele @steele_bob RT @Smiles4Nana: @DavidCookeMD So true! #lcsm proud to be a part of it! |
| Hossen Mahmud, MD @DrHMahmudMD RT @JFreemanDaily: T1: T1: #WCLC2017 is a great opportunity for networking among #lungcancer researchers and clinicians #lcsm |
| Danielle Pardue @Actorielle RT @Smiles4Nana: @GraceCordovano @JFreemanDaily I feel like saving lives should always be universally recommended #lcsm |
| Faces of Lung Cancer @LungCancerFaces @cpeedell @BrendonStilesMD Fight for your life sounds about right... #lcsm |
 | Britnie Lynn @brltkhaos RT @Smiles4Nana: T4: T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM |
| Brendon Stiles @BrendonStilesMD @_ShankarSiva @cpeedell Pharma needs to be engaged or they will be overrun by studies by people with a much different agenda. #lcsm |
| #LCSM Chat @lcsmchat RT @ChancesR3: @EdenLake @steele_bob Even late stage. My husband being eval for 5th line treatment - duvalumab and AZD6738. Immunotherapy that might work with EGFR. #lcsm #hope |
| Danielle Pardue @Actorielle RT @LungCancerFaces: @cpeedell @BrendonStilesMD Fight for your life sounds about right... #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: @_ShankarSiva @cpeedell Pharma needs to be engaged or they will be overrun by studies by people with a much different agenda. #lcsm |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: @GraceCordovano @JFreemanDaily I feel like saving lives should always be universally recommended #lcsm |
| Naomi @ChancesR3 @EdenLake @steele_bob Thank you! #lcsm |
| Brendon Stiles @BrendonStilesMD @Smiles4Nana @GraceCordovano @JFreemanDaily I agree and I will put this forward a universal proposal for all societies! #lcsm |
| Tiffini Joseph @Smiles4Nana @IntrovertinNC @GraceCordovano @JFreemanDaily Common sense...not so common, sadly #lcsm |
| Janet Freeman-Daily @JFreemanDaily @GraceCordovano @Smiles4Nana Much work necessary to make broad molecular testing affordable and covered for all #lungcancer patients. #lcsm |
| Tiffini Joseph @Smiles4Nana RT @JFreemanDaily: @GraceCordovano @Smiles4Nana Much work necessary to make broad molecular testing affordable and covered for all #lungcancer patients. #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: @GraceCordovano @Smiles4Nana Much work necessary to make broad molecular testing affordable and covered for all #lungcancer patients. #lcsm |
| Brendon Stiles @BrendonStilesMD Great science. Great trials. Great conversation. Coming to T5. #lcsm |
| Danielle Pardue @Actorielle RT @Smiles4Nana: @IntrovertinNC @GraceCordovano @JFreemanDaily Common sense...not so common, sadly #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: @Smiles4Nana @GraceCordovano @JFreemanDaily I agree and I will put this forward a universal proposal for all societies! #lcsm |
 | Christopher Donley @onehandedpotter RT @JFreemanDaily: T4: T4: Update on data for lorlatinib to treat ALK+ and ROS1+ NSCLC #WCLC2017 #LCSM https://t.co/JuilMOafVr |
| Shankar Siva @_ShankarSiva @cpeedell @BrendonStilesMD T4 - yes the UK are usually leaders in pragmatic trials no one else can do #lcsm |
| Brendon Stiles @BrendonStilesMD T5: Were there any exciting new areas of translational research that show particular promise for patients with lung cancer? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @_ShankarSiva @cpeedell Pharma needs to be engaged or they will be overrun by studies by people with a much different agenda. #lcsm |
| Tiffini Joseph @Smiles4Nana RT @BrendonStilesMD: Great science. Great trials. Great conversation. Coming to T5. #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: @_ShankarSiva @cpeedell Pharma needs to be engaged or they will be overrun by studies by people with a much different agenda. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @GraceCordovano @Smiles4Nana Much work necessary to make broad molecular testing affordable and covered for all #lungcancer patients. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T5: T5: Were there any exciting new areas of translational research that show particular promise for patients with lung cancer? #lcsm |
| #LCSM Chat @lcsmchat RT @_ShankarSiva: @cpeedell @BrendonStilesMD T4 - yes the UK are usually leaders in pragmatic trials no one else can do #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5: T5: Were there any exciting new areas of translational research that show particular promise for patients with lung cancer? #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Continued investigation into tumor heterogeneity – how different parts of tumors are distinct – is quite important. #lcsm |
 | Shereese Maynard, MS; MBA 😷 She/Her @ShereeseMayMba RT @findlungcancer: The results by the numbers Liverpool #lungcancer screening project #lcsm https://t.co/wysFTMlH1U |
| Janet Freeman-Daily @JFreemanDaily T5: Dr. Julie Brahmer from @HopkinsMedicine & top experts discussed possible new #biomarkers for #lungcancer #Immunotherapy #LCSM #WCLC2017 https://t.co/mlzo9IqaO0 |
| Brendon Stiles @BrendonStilesMD T5. Also love molecular characterization of different adeno subtypes (ID 9412). Adenocarcinomas are quite different cancers. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T5. Continued investigation into tumor heterogeneity – how different parts of tumors are distinct – is quite important. #lcsm |
| Hossen Mahmud, MD @DrHMahmudMD @BrendonStilesMD That was interesting to hear many inputs from many people. #LCSM https://t.co/Rrmp6hsYwV |
 | Mr.Sixtyniner™ @lilltwit86 RT @Smiles4Nana: T4: T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM |
| Tiffini Joseph @Smiles4Nana RT @BrendonStilesMD: T5. Continued investigation into tumor heterogeneity – how different parts of tumors are distinct – is quite important. #lcsm |
| Lung Cancer Sux @LungCancerSux RT @BrendonStilesMD: T5. Also love molecular characterization of different adeno subtypes (ID 9412). Adenocarcinomas are quite different cancers. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Continued investigation into tumor heterogeneity – how different parts of tumors are distinct – is quite important. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T5: T5: Dr. Julie Brahmer from @HopkinsMedicine & top experts discussed possible new #biomarkers for #lungcancer #Immunotherapy #LCSM #WCLC2017 https://t.co/mlzo9IqaO0 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Also love molecular characterization of different adeno subtypes (ID 9412). Adenocarcinomas are quite different cancers. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. In ref to screening: Work on germline mutations from Ohio State, ID8670. Are some patients genetically predisposed to lung cancer? #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T5: T5: Dr. Julie Brahmer from @HopkinsMedicine & top experts discussed possible new #biomarkers for #lungcancer #Immunotherapy #LCSM #WCLC2017 https://t.co/mlzo9IqaO0 |
| #LCSM Chat @lcsmchat RT @DrHMahmud: @BrendonStilesMD That was interesting to hear many inputs from many people. #LCSM https://t.co/Rrmp6hsYwV |
| Naomi @ChancesR3 RT @BrendonStilesMD: T5. Continued investigation into tumor heterogeneity – how different parts of tumors are distinct – is quite important. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T5. Also love molecular characterization of different adeno subtypes (ID 9412). Adenocarcinomas are quite different cancers. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T5. In ref to screening: T5. In ref to screening: Work on germline mutations from Ohio State, ID8670. Are some patients genetically predisposed to lung cancer? #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Interesting to see possibility of discordant PD-L1 results from same patient (22.2% in ID 10357). ? value of repeat test. #lcsm |
| Naomi @ChancesR3 RT @BrendonStilesMD: T5. In ref to screening: T5. In ref to screening: Work on germline mutations from Ohio State, ID8670. Are some patients genetically predisposed to lung cancer? #lcsm |
 | Jim Saladin @jsinkc439 RT @BrendonStilesMD: T4. Still bouncing around - who should get frontline immunotherapy for NSCLC? #lcsm |
| Deb Smith 🌻🟧 @debsmithbeach RT @_ShankarSiva: T3 & T4 aLots to be excited about with improvements from trials over the years in stage III (yellow) and stage IV NSCLV #LCSM @wallyjc https://t.co/uGDGsF7CyF |
| Tiffini Joseph @Smiles4Nana @BrendonStilesMD I always wonder this. Why one smoker gets LC yet another doesn’t. Why does is run rampant through some families, yet some are isolated #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Interesting to see possibility of discordant PD-L1 testing results from same patient (22.2% in ID 10357). ? value of repeat test. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @EdenLake Not so fast ... why give stage 1 patients targeted therapies (which can't cure) when they can have curative treatment? #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T5. Interesting to see possibility of discordant PD-L1 results from same patient (22.2% in ID 10357). ? value of repeat test. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Continued work on tumor mutation burden as predictor of immune response (ID 11063) #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T5. Interesting to see possibility of discordant PD-L1 testing results from same patient (22.2% in ID 10357). ? value of repeat test. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. In ref to screening: T5. In ref to screening: Work on germline mutations from Ohio State, ID8670. Are some patients genetically predisposed to lung cancer? #lcsm |
| Andrea Borondy Kitts @findlungcancer implementation waits for NELSON trail results; if imp mortality similar NLST will go ahead; if no impvmt will not; results in 1 year #lcsm https://t.co/ThBIzoWzXJ |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Interesting to see possibility of discordant PD-L1 results from same patient (22.2% in ID 10357). ? value of repeat test. #lcsm |
| #LCSM Chat @lcsmchat RT @Smiles4Nana: @BrendonStilesMD I always wonder this. Why one smoker gets LC yet another doesn’t. Why does is run rampant through some families, yet some are isolated #lcsm |
| Brendon Stiles @BrendonStilesMD @Smiles4Nana Has to be something genetic there somewhere. Just haven't found it yet. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Interesting to see possibility of discordant PD-L1 testing results from same patient (22.2% in ID 10357). ? value of repeat test. #lcsm |
| Ian Pereira @IanJPereira RT @JFreemanDaily: T3: T3: #WCLC2017 had some great presentations on how to decide whether a lung nodule required action #lcsm |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: @JFreemanDaily This key. Be thoughtful and do no harm. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @EdenLake Not so fast ... why give stage 1 patients targeted therapies (which can't cure) when they can have curative treatment? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Continued work on tumor mutation burden as predictor of immune response (ID 11063) #lcsm |
| #LCSM Chat @lcsmchat RT @findlungcancer: implementation waits for NELSON trail results; if imp mortality similar NLST will go ahead; if no impvmt will not; results in 1 year #lcsm https://t.co/ThBIzoWzXJ |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: T3. Reminder that lung cancer in never smokers not an indolent disease: T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn't so Innocent #lcsm |
| Janet Freeman-Daily @JFreemanDaily T5: Nice to see analysis of Patient Reported Outcomes from a big trial; hope to see more of this in clinical trials #lcsm |
| Brendon Stiles @BrendonStilesMD T5. More work on circulating free DNA as a biomarker and as a measure of response/recurrence. Will play increasing role. #lcsm |
| Shankar Siva @_ShankarSiva T5 - re: great trials, have to mention CHISEL by my boss; first trial of technology in oncology (that I know) with a survival benefit #lcsm https://t.co/pASby1iwQD |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T5. Continued work on tumor mutation burden as predictor of immune response (ID 11063) #lcsm |
| Danielle Pardue @Actorielle RT @findlungcancer: implementation waits for NELSON trail results; if imp mortality similar NLST will go ahead; if no impvmt will not; results in 1 year #lcsm https://t.co/ThBIzoWzXJ |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: @Smiles4Nana Has to be something genetic there somewhere. Just haven't found it yet. #lcsm |
| Tiffini Joseph @Smiles4Nana @BrendonStilesMD Even more reason LC needs a bigger piece of the research pie #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T5: T5: Nice to see analysis of Patient Reported Outcomes from a big trial; hope to see more of this in clinical trials #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T5. More work on circulating free DNA as a biomarker and as a measure of response/recurrence. Will play increasing role. #lcsm |
| Ian Pereira @IanJPereira #RadOnc https://t.co/Op5pWw2Atm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T5: T5: Nice to see analysis of Patient Reported Outcomes from a big trial; hope to see more of this in clinical trials #lcsm |
| Tiffini Joseph @Smiles4Nana RT @_ShankarSiva: T5 - re: T5 - re: great trials, have to mention CHISEL by my boss; first trial of technology in oncology (that I know) with a survival benefit #lcsm https://t.co/pASby1iwQD |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. More work on circulating free DNA as a biomarker and as a measure of response/recurrence. Will play increasing role. #lcsm |
 | Marita Lesch @MaritaLesch1 RT @OncologyTimes: NSCLC Survival Rates Higher Among Patients Treated at Academic Centers #WCLC2017 https://t.co/VtFCAnWV1w #lungcancer #lcsm https://t.co/NRkcijMRST |
| Janet Freeman-Daily @JFreemanDaily @EdenLake Stage 1 is typically treated with surgery, curative in 80%+ of cases. Better option than targeted therapy. #lcsm |
| Andrea Borondy Kitts @findlungcancer @trvanes @JFreemanDaily Yes I talked to presenter & implementation decision is awaiting NELSON trial results, all data in 6 weeks ago; 1 year for results #lcsm |
| Brendon Stiles @BrendonStilesMD Just about time to wrap up. Lively chat although I suspect many #wclc2017 peeps are still drowning in sake. Closing thoughts? #lcsm |
| Brendon Stiles @BrendonStilesMD @cpeedell Impressive rally. Thanks for joining and for always insightful comments. #lcsm |
| Brendon Stiles @BrendonStilesMD @Smiles4Nana Like....gigantic. #lcsm |
| Danielle Pardue @Actorielle RT @_ShankarSiva: T5 - re: T5 - re: great trials, have to mention CHISEL by my boss; first trial of technology in oncology (that I know) with a survival benefit #lcsm https://t.co/pASby1iwQD |
| Brendon Stiles @BrendonStilesMD Link to meeting site: https://t.co/i2pm35lAtm #lcsm |
| Danielle Pardue @Actorielle RT @Smiles4Nana: @BrendonStilesMD Even more reason LC needs a bigger piece of the research pie #lcsm |
| Brendon Stiles @BrendonStilesMD Press highlights: https://t.co/LjsICl2Sn3 PD-L1, exercise, community awareness #lcsm |
| Tiffini Joseph @Smiles4Nana Great chat!! Thank you lcsm https://t.co/6sgoFg2Wjk |
| Bob Steele @steele_bob RT @BrendonStilesMD: Link to meeting site: Link to meeting site: https://t.co/i2pm35lAtm #lcsm |
 | Annie Heckenberger @anniemal @BrendonStilesMD @Smiles4Nana Based on my family history and nothing more, I have to say yes. #lcsm |
| #LCSM Chat @lcsmchat RT @_ShankarSiva: T5 - re: T5 - re: great trials, have to mention CHISEL by my boss; first trial of technology in oncology (that I know) with a survival benefit #lcsm https://t.co/pASby1iwQD |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: Link to meeting site: Link to meeting site: https://t.co/i2pm35lAtm #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: Press highlights: Press highlights: https://t.co/LjsICl2Sn3 PD-L1, exercise, community awareness #lcsm |
| Janet Freeman-Daily @JFreemanDaily CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm |
| #LCSM Chat @lcsmchat RT @cpeedell: |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @EdenLake Stage 1 is typically treated with surgery, curative in 80%+ of cases. Better option than targeted therapy. #lcsm |
| #LCSM Chat @lcsmchat RT @findlungcancer: @trvanes @JFreemanDaily Yes I talked to presenter & implementation decision is awaiting NELSON trial results, all data in 6 weeks ago; 1 year for results #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Just about time to wrap up. Lively chat although I suspect many #wclc2017 peeps are still drowning in sake. Closing thoughts? #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: CT: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm |
| Brendon Stiles @BrendonStilesMD For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wclc2017 #lcsm |
| Faces of Lung Cancer @LungCancerFaces Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiXZv9w We need you #lcsm |
| Andrea Borondy Kitts @findlungcancer CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for Toronto 2018 #LCSM |
| Brendon Stiles @BrendonStilesMD Great chat. Thanks everyone for sharing your insight. Get ready for #LCAM starting in November. Let’s make some noise! #lcsm |
| Geri Massa @GeriGerim13 Thank Y’all for the chat, I have a lot to learn 😊 #lcsm |
| Bob Steele @steele_bob RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiXZv9w We need you #lcsm |
| Lung Cancer Sux @LungCancerSux RT @BrendonStilesMD: Link to meeting site: Link to meeting site: https://t.co/i2pm35lAtm #lcsm |
| Brendon Stiles @BrendonStilesMD RT @findlungcancer: CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for Toronto 2018 #LCSM |
| Brendon Stiles @BrendonStilesMD Hope everyone makes it! #lcsm https://t.co/PfMMxWM28z |
| Denise Cutlip @dennycee RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiXZv9w We need you #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: CT: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wclc2017 #lcsm |
| Brendon Stiles @BrendonStilesMD RT @JFreemanDaily: CT: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm |
| Danielle Pardue @Actorielle RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiXZv9w We need you #lcsm |
 | A.pretty.girl @nenadomlnadora RT @Smiles4Nana: T4: T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM |
| Tiffini Joseph @Smiles4Nana @anniemal @BrendonStilesMD https://t.co/PVYR2jzyj1-quit smoking 20 yrs b4 dx, same with maternal Uncle, maternal gma neversmoker. Can’t tell me it’s not genetic #lcsm |
| Danielle Pardue @Actorielle RT @findlungcancer: CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for Toronto 2018 #LCSM |
| Ian Pereira @IanJPereira RT @cpeedell: |
| Tiffini Joseph @Smiles4Nana RT @JFreemanDaily: CT: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: Hope everyone makes it! #lcsm https://t.co/PfMMxWM28z |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: @_ShankarSiva @cpeedell Pharma needs to be engaged or they will be overrun by studies by people with a much different agenda. #lcsm |
| Tiffini Joseph @Smiles4Nana RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiXZv9w We need you #lcsm |
| Danielle Pardue @Actorielle Thank you so much, my friends! Wonderful hour as always! #lcsm |
| Andrea Borondy Kitts @findlungcancer RT @BrendonStilesMD: Press highlights: Press highlights: https://t.co/LjsICl2Sn3 PD-L1, exercise, community awareness #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Link to meeting site: Link to meeting site: https://t.co/i2pm35lAtm #lcsm |
| Bob Steele @steele_bob Now I can take my Delsym & Codeine. Good night all. Look forward to seeing you again in 2 weeks. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Press highlights: Press highlights: https://t.co/LjsICl2Sn3 PD-L1, exercise, community awareness #lcsm |
| Brendon Stiles @BrendonStilesMD Thanks everyone. Have a great night! Keep talking about #LungCancer. We are making a difference in real people's lives. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: CT: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wclc2017 #lcsm |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiXZv9w We need you #lcsm |
| Janet Freeman-Daily @JFreemanDaily Thanks to @brendonstilesMD for finding great chat topic, moderating, and pulling together highlights so soon after #WCLC2017! #lcsm |
| #LCSM Chat @lcsmchat RT @findlungcancer: CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for Toronto 2018 #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Great chat. Thanks everyone for sharing your insight. Get ready for #LCAM starting in November. Let’s make some noise! #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: Thanks to @brendonstilesMD for finding great chat topic, moderating, and pulling together highlights so soon after #WCLC2017! #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: Thanks everyone. Have a great night! Keep talking about #LungCancer. We are making a difference in real people's lives. #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: Thanks to @brendonstilesMD for finding great chat topic, moderating, and pulling together highlights so soon after #WCLC2017! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiXZv9w We need you #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Thanks everyone. Have a great night! Keep talking about #LungCancer. We are making a difference in real people's lives. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Thanks to @brendonstilesMD for finding great chat topic, moderating, and pulling together highlights so soon after #WCLC2017! #lcsm |
| Shankar Siva @_ShankarSiva Thank you @BrendonStilesMD for moderating - it’s the first chat I’ve engaged with! Been fun, let’s get back to work on lungcancer #lcsm |
| Ian Pereira @IanJPereira @cpeedell @BrendonStilesMD @_ShankarSiva I wond and if Canada & other countries exert the same buyer power to keep prices in check. #lcsm #cdnpoli #onpoli T4 #pharmacare? |
 | Antosha Z. Corbinski @davies42g RT @cpeedell: |
| #LCSM Chat @lcsmchat RT @_ShankarSiva: Thank you @BrendonStilesMD for moderating - it’s the first chat I’ve engaged with! Been fun, let’s get back to work on lungcancer #lcsm |
| Ian Pereira @IanJPereira RT @JFreemanDaily: @GraceCordovano @Smiles4Nana Much work necessary to make broad molecular testing affordable and covered for all #lungcancer patients. #lcsm |
 | Savvy Cooperative | #AskPatients @savvy_coop RT @GraceCordovano: Amazing how following that “something” connects u w/most incredible people along the way. #hcldr #bcsm #lcsm #patientchat @S4PM @savvy_coop https://t.co/Pho2eoPZLm |
| Janet Freeman-Daily @JFreemanDaily @EdenLake Sorry you had issues complicating treatment (kidney and heart conditions might also prevent treatment with targeted therapy) #LCSM |
| Ian Pereira @IanJPereira #RadOnc https://t.co/uZWFCOgeAD |
| Treatment for Cancer @cancer_tm RT @NCICancerStats: Death rates for #LungCancer have been falling on average 2.5% each year between 2005-2014. Learn more: https://t.co/JV6sVLEnLw #LCSM https://t.co/XpVifiPiDV |
| Ian Pereira @IanJPereira RT @JFreemanDaily: CT: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm |
| Ian Pereira @IanJPereira RT @BrendonStilesMD: For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wclc2017 #lcsm |
| Ian Pereira @IanJPereira RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiXZv9w We need you #lcsm |
| Ian Pereira @IanJPereira RT @findlungcancer: CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for Toronto 2018 #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @findlungcancer: CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for Toronto 2018 #LCSM |
| Dr. David Tom Cooke @DavidCookeMD RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiXZv9w We need you #lcsm |
| Naomi @ChancesR3 @EdenLake I'm sending you support Eden. Sorry we haven't connected much but you are in my thoughts. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @BrendonStilesMD: For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wclc2017 #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @JFreemanDaily: CT: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm |
| Naomi @ChancesR3 RT @BrendonStilesMD: Link to meeting site: Link to meeting site: https://t.co/i2pm35lAtm #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @JFreemanDaily: @EdenLake Stage 1 is typically treated with surgery, curative in 80%+ of cases. Better option than targeted therapy. #lcsm |
| Dr. David Tom Cooke @DavidCookeMD RT @OncologyTimes: NSCLC Survival Rates Higher Among Patients Treated at Academic Centers #WCLC2017 https://t.co/VtFCAnWV1w #lungcancer #lcsm https://t.co/NRkcijMRST |
 | Lung Cancer #1 cancer killer of women @VirginiaMByrne RT @BrendonStilesMD: For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wclc2017 #lcsm |
| Ian Pereira @IanJPereira Thanks #lcsm for your insights. Looking forward to #wclc2018 & everything in between. |
| Lung Cancer #1 cancer killer of women @VirginiaMByrne RT @Smiles4Nana: @BrendonStilesMD Even more reason LC needs a bigger piece of the research pie #lcsm |
 | 🇺🇸Ashley🇺🇸 @kymama16 RT @JFreemanDaily: CT: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm |
| Andrea Borondy Kitts @findlungcancer @BrendonStilesMD lot of comments from people that they found it helpful/impactful to hear patient perspective #lungcancer screening #LCSM #wclc2017 |
#LCSM content from Twitter.